Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Gujarat Kidney And Super Speciality EV-to-EBIT?
Gujarat Kidney And Super SpecialityNSE:GKSL -0.05%19 EV-to-EBIT is 62.58 as of Aug. 26, 2026, which is 71% above its 10-year median of 36.52. GuruFocus rates NSE:GKSL with a GF Score™ of 19/100. The stock has 6 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Gujarat Kidney And Super Speciality ranks worse than 89.71% on this metric.
NSE:GKSL'
s EV-to-EBIT Range Over the Past 10 Years
Min: 29.84 Med: 36.52 Max: 62.61
Current: 62.58
During the past 4 years, the highest EV-to-EBIT of Gujarat Kidney And Super Speciality was 62.61. The lowest was 29.84. And the median was 36.52.
NSE:GKSL's EV-to-EBIT is ranked worse than 89.71% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 15.905
vs NSE:GKSL: 62.58
Gujarat Kidney And Super Speciality (NSE:GKSL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Gujarat Kidney And Super Speciality's Enterprise Value for the quarter that ended in Jun. 2026 was ₹10,202.3 Mil.
Gujarat Kidney And Super Speciality's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹187.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality EV-to-EBIT Related Terms
Gujarat Kidney And Super Speciality EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality EV-to-EBIT Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EV-to-EBIT
0.00
0.00
0.00
33.35
Gujarat Kidney And Super Speciality Quarterly Data
For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Kidney And Super Speciality EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Gujarat Kidney And Super Speciality's EV-to-EBIT falls into.
Gujarat Kidney And Super Speciality's current Enterprise Value is ₹11,738.8 Mil.
Gujarat Kidney And Super Speciality's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹187.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality (NSE:GKSL) has a EV-to-EBIT of 62.58 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gujarat Kidney And Super Speciality and its competitors. This is 71% above median its historical median of 36.52. Over the past decade, Gujarat Kidney And Super Speciality's EV-to-EBIT has ranged from 29.84 to 62.61. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #427 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 89.7%.
Is Gujarat Kidney And Super Speciality's EV-to-EBIT too high?
Gujarat Kidney And Super Speciality's current EV-to-EBIT of 62.58 is 71% above median its 10-year median of 36.52. Over the past 10 years, this metric has ranged from a low of 29.84 to a high of 62.61. The Healthcare Providers & Services industry median EV-to-EBIT is 15.91. Gujarat Kidney And Super Speciality's value of 62.58 is 293.5% above this industry median. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #427 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #427 out of 476 companies for EV-to-EBIT. This places Gujarat Kidney And Super Speciality in the lower half of its industry. The industry median EV-to-EBIT is 15.91. Gujarat Kidney And Super Speciality's value of 62.58 is 293.5% above this benchmark. Historically, Gujarat Kidney And Super Speciality's own EV-to-EBIT has ranged from 29.84 to 62.61 over the past decade. While the company's 10-year median is 36.52 vs. the industry median of 15.91, Gujarat Kidney And Super Speciality has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.91, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Kidney And Super Speciality's current EV-to-EBIT of 62.58 is 293.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current EV-to-EBIT is 62.58, which is 71% above median its own 10-year median of 36.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current EV-to-EBIT of 62.58. The current EV-to-EBIT is 62.58, which is 71% above median its 10-year median of 36.52 and 293.5% above the Healthcare Providers & Services industry median of 15.91. Gujarat Kidney And Super Speciality's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current EV-to-EBIT is 62.58 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
19GF Score
Get the complete analysis for NSE:GKSL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 
